Markets Ladenburg starts Ovid Therapeutics at buy; PT $27 Ladenburg Thalmann initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with a “buy” rating and $27 price target. The stock closed at $10.14 on April 19. Ovid is developing two clinical-stage candidates: OV101, a GABA... April 20, 2018